— Conagra Brands (NYSE: CAG) reported adjusted earnings of $0.63 per share for the second quarter of 2020, vs. $0.57 per share expected.
— Net income attributable to Conagra Brands increased to $260.5 million or $0.53 per share from $131.6 million or $0.31 per share last year
— Second-quarter net sales increased 18.3% to $2.82 billion, vs. $2.8 billion expected; organic net sales increased by 1.6%
— The integration of Pinnacle remained on-track, with around $42 million of incremental cost synergies realized during the quarter
— Updated total targeted annual cost synergies for the Pinnacle acquisition from $285 million to $305 million, by the end of fiscal 2022
— Adjusted EBITDA increased 17.2% to $610 million in the quarter
— Expects organic net sales growth to be 1%-1.5% in fiscal 2020; sees full-year reported net sales growth between 12.4% and 12.9%
— Expects adjusted earnings from continuing operations to be in the range of $2.07 per share to $2.17 per share in fiscal 2020
— Looking for full-year free cash flow that is slightly below $1 billion, which is unchanged from the prior guidance
Most Popular
DIS Earnings: All you need to know about Walt Disney’s Q4 2025 earnings results
The Walt Disney Company (NYSE: DIS) reported its fourth quarter 2025 earnings results today. Revenues of $22.5 billion were comparable to the year-ago quarter. Net income attributable to The Walt
Cisco (CSCO) reports higher Q1 revenue and earnings; results beat estimates
Network gear maker Cisco Systems Inc. (NASDAQ: CSCO) on Wednesday announced financial results for the first quarter of fiscal 2026, reporting higher revenue and profit. Earnings, on an adjusted basis,
Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies and solid tumors. In an email conversation with
Comments
Comments are closed.